An update on risk factors, prognosis and management of melanoma patients

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 1, 2012, Pages 1-19

  Jaimes, N ^a   Marghoob, A A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Melanoma; Nevus; Risk factors; Ultraviolet rays

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2 INHIBITOR; DACARBAZINE; INTERFERON; INTERLEUKIN 2; MELANOCORTIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SUNSCREEN; VEMURAFENIB;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CONGENITAL NEVUS; DYSPLASTIC NEVUS; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; GENE MUTATION; HUMAN; LOW DRUG DOSE; MEDICAL PHOTOGRAPHY; MELANOCYTIC NEVUS; MELANOMA; NEVUS; NON MELANOMA SKIN CANCER; PARKINSON DISEASE; PRIMARY PREVENTION; PUVA; REVIEW; RISK FACTOR; SKIN EXAMINATION; SUN EXPOSURE; XERODERMA PIGMENTOSUM;

EID: 84860777605     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007;57;555-72; quiz 573-56.
2. Coleman MP AD, Albreht T, McKee M. Responding to the challenge of cancer in Europe. [cited 2011 November 3]. Available at: http://www.euro.who.int-data/ assets/pdf-file/0011/97823/E91137.pdf.
3. Cancer Council Australia. Cancer Council Australia, Melanoma. Incidence and mortality, 2011.
4. American Cancer Society. Cancer Facts & Figures 2011. American Cancer Society. Atlanta, 2011.
5. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61;212-36.
6. Perez-Losada J, Castellanos-Martin A, Mao JH. Cancer evolution and individual susceptibility. Integrative biology : quantitative biosciences from nano to macro. Integr Biol (Camb) 2011;3:316-28.
7. Churchill FB. William Johannsen and the genotype concept. Journal of the history of biology. J Hist Biol 1974;7:5-30.
8. Surveillance epidemiology and end results (SEER). Melanoma Incidence and Mortality. 2011.
9. Chamberlain AJ, Fritschi L, Giles GG, Dowling JP, Kelly JW. Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. Arch Dermatol 2002;138;609-14.
10. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011;65;S 17-S25 e13.
11. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41;2040-59. (Pubitemid 41337946)
12. Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta-analysis and estimates of attributable fraction. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010;19:65-73.
13. Begg CB, Hummer A, Mujumdar U, Armstrong BK, Kricker A, Marrett LD et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes & Control CCC 2004;15;957-65.
14. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97;1507-15. (Pubitemid 41631950)
15. Mocellin S, Verdi D, Nitti D. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis 2009;30; 1735-43.
16. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353;2135-47. (Pubitemid 41653105)
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002;417;949-54. (Pubitemid 34716871)
18. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130;20-7.
19. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24;4340-6. (Pubitemid 46630793)
20. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16;471-8. (Pubitemid 44934704)
21. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14;6821-8.
22. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. High frequency of BRAF mutations in nevi. Nature genetics 2003;33;19-20. (Pubitemid 36068675)
23. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003;95;1878-90.
24. Fargnoli MC, Argenziano G, Zalaudek I, Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 2006;6;657-70. (Pubitemid 44192883)
25. Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med 2006;355;51-65.
26. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. Journal of medical genetics. J Med Genet 2007;44;99-106.
27. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiology, Biomarkers and Prevention 2006;15;1520-5. (Pubitemid 44299326)
28. Berwick M, Begg CB, Armstrong BK, Reiner AS, Thomas NE, Cook LS et al. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. J Invest Dermatol 2011 [Epub ahead of print].
29. Bergman W, Gruis N. Familial melanoma and pancreatic cancer. N Engl J Med 1996;334;471-2.
30. Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocyte nevi, and cutaneous melanoma. J Am Acad Dermatol 2003;49;865-72. (Pubitemid 37314875)
31. Mar V, Wolfe R, Kelly JW. Predicting melanoma risk for the Australian population. Australas J Dermatol 2011;52;109-16.
32. Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? American journal of Human Genetics 2000;66;176-86. (Pubitemid 30481481)
33. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001;137;1477-85. (Pubitemid 33064243)
34. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. International journal of cancer Journal International du Cancer 2011;129;1730-40.
35. Cuellar F, Puig S, Kolm I, Puig-Butille J, Zaballos P, Marti-Laborda R et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br J Dermatol 2009;160;48-53.
36. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends in Molecular Medicine 2006;12;406-14. (Pubitemid 44291572)
37. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-6.
38. Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer 2010;46;1413-20.
39. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41;28-44. (Pubitemid 40029657)
40. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003;139;282-8. (Pubitemid 36330574)
41. Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch Dermatol 2003;139;1620-4; discussion 1624.
42. Wachsmuth RC, Gaut RM, Barrett JH, Saunders CL, Randerson-Moor JA, Eldridge A et al. Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 2001;117;348-52. (Pubitemid 34205721)
43. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001;93;678-83. (Pubitemid 32492808)
44. Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma compared with superficial spreading melanoma: a case-control study in Australia
45. Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for melanoma. Int J Dermatol 2010;49;362-76.
46. Lynch HT, Fusaro RM, Danes BS, Kimberling WJ, Lynch JF. A review of hereditary malignant melanoma including biomarkers in familial atypical multiple mole melanoma syndrome. Cancer Genet Cytogenet 1983;8;325-58. (Pubitemid 13060678)
47. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995;32;479-94.
48. Marghoob AA, Kopf AW, Rigel DS, Bart RS, Friedman RJ, Yadav S et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study. Arch Dermatol 1994;130;993-8. (Pubitemid 24255030)
49. Halpern AC, Guerry Dt, Elder DE, Clark WH Jr, Synnestvedt M, Norman S et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991;127;995-9.
50. Augustsson A, Stierner U, Rosdahl I, Suurkula M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991;71;518-24.
51. de Giorgi V, Rossari S, Papi F, Gori A, Alfaioli B, Grazzini M et al. Multiple primary melanoma: the impact of atypical naevi and follow-up. Br J Dermatol 2010;163:1319-22.
52. High WA, Robinson WA. Genetic mutations involved in melanoma: a summary of our current understanding. Advances in Dermatology 2007;23;61-79.
53. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277;1439-44. (Pubitemid 27208885)
54. Lipoff JB, Scope A, Dusza SW, Marghoob AA, Oliveria SA, Halpern AC. Complex dermoscopic pattern: a potential risk marker for melanoma. Br J Dermatol 2008;158;821-4. (Pubitemid 351415713)
55. Scope A, Marghoob AA, Dusza SW, Satagopan JM, Agero AL, Benvenuto-Andrade C et al. Dermoscopic patterns of naevi in fifth grade children of the Framingham school system. Br J Dermatol 2008;158;1041-9. (Pubitemid 351521464)
56. Tromberg J, Bauer B, Benvenuto-Andrade C, Marghoob AA. Congenital melanocytic nevi needing treatment. Dermatol Ther 2005;18;136-50. (Pubitemid 40934407)
57. Ceballos PI, Ruiz-Maldonado R, Mihm MC, Jr. Melanoma in children. N Engl J Med 1995;332:656-62.
58. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006;155;1-8. (Pubitemid 43876386)
59. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294;1647-54. (Pubitemid 41407357)
60. Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB et al. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 2011 [Epub ahead of print].
61. Thomas NE, Kricker A, From L, Busam K, Millikan RC, Ritchey ME et al. Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiology, Biomarkers and Prevention 2010;19;2932-41.
62. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95;806-12. (Pubitemid 36798427)
63. Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995;75;707-14.
64. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348;1681-91. (Pubitemid 36459475)
65. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol 2011;65;S69-77.
66. Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994;130;1018-21. (Pubitemid 24255035)
67. Wang Y, Digiovanna JJ, Stern JB, Hornyak TJ, Raffeld M, Khan SG et al. Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci U S A. 2009;106;6279-6284.
68. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011;76;2002-9.
69. von Thaler AK, Kamenisch Y, Berneburg M. The role of ultraviolet radiation in melanomagenesis. Exp Dermatol 2010;19;81-8.
70. Weinstock MA, Fisher DE. Indoor ultraviolet tanning: what the data do and do not show regarding risk of melanoma and keratinocyte malignancies. J Natl Compr Canc Netw 2010;8;867-72; quiz 873.
71. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V et al. A review of human carcinogens - part D: radiation. Lancet Oncol 2009;10;751-2.
72. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463;191-6.
73. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41;45-60. (Pubitemid 40029658)
74. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nest-ed case-control study within the Nurses' Health Study. Int J Epidemiol 2006;35;1514-21. (Pubitemid 46178928)
75. IARC Working Group. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. International journal of cancer Journal International du Cancer 2007;120;1116-22.
76. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44;755-61. (Pubitemid 32391161)
77. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27;6199-206.
78. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011;29;2199-205.
79. Bichakjian CK, Halpern AC, Johnson TM, Foote Hood A, Grichnik JM, Swetter SM et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2011;65;1032-47.
80. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR et al. Multivariate analysis of prognostic factors among 2,313 patients with stage UI melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28;2452-9.
81. Paradela S, Fonseca E, Prieto VG. Melanoma in children. Arch Pathol Lab Med 2011;135;307-16.
82. Lewis KG. Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol Surg 2008;34;152-9.
83. Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg 2006;132;370-3.
84. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg 2011;253;1155-64.
85. Pollack LA, Li J, Berkowitz Z, Weir HK, Wu XC, Ajani UA et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011;65;S78-86.
86. Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 2011;167;192-8.
87. Sladden MJ, Balch C, Barzilai DA, Berg D, Freiman A, Handiside T et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 2009;CD004835.
88. Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Mansson-Brahme E et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011 [Epub ahead of print].
89. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V et al. Melanoma. J Natl Compr Canc Netw 2009;7;250-75.
90. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363;711-23.
91. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364;2507-16.
92. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clinic proceedings Mayo Clinic 2007;82;364-80.
93. Lautenschlager S, Wulf HC, Pittelkow MR. Photoprotection. Lancet 2007;370;528-37. (Pubitemid 47212348)
94. Gambichler T, Laperre J, Hoffmann K. The European standard for sun-protective clothing: EN 13758. J Eur Acad Dermatol Venereol 2006;20;125-30. (Pubitemid 43740509)
95. Tuchinda C, Srivannaboon S, Lim HW. Photoprotection by window glass, automobile glass, and sunglasses. J Am Acad Dermatol 2006;54;845-54.
96. European Commission. Commission recommendation on the efficacy of sunscreen products and the claims made relating thereto. Official Journal of the European Union; 2006.
97. Wang SQ, Lim HW. Current status of the sunscreen regulation in the United States: 2011 Food and Drug Administration's final rule on labeling and effectiveness testing. J Am Acad Dermatol 2011;65;863-9.
98. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2010 [Epub ahead of print].
99. van der Leest RJ, de Vries E, Bulliard JL, Paoli J, Peris K, Stratigos AJ et al. The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010. J Eur Acad Dermatol Venereol 2011 [Epub ahead of print].
100. Dobbinson SJ, Wakefield MA, Jamsen KM, Herd NL, Spinal MJ, Lipscomb JE et al. Weekend sun protection and sunburn in Australia trends (1987-2002) and association with SunSmart television advertising. American Journal of Preventive Medicine 2008;34;94-101.
101. Hill D, White V, Marks R, Borland R. Changes in sun-related attitudes and behaviours, and reduced sunburn prevalence in a population at high risk of melanoma. Eur J Cancer Prev 1993;2:447-56. (Pubitemid 2013057)
102. Bonovas S, Nikolopoulos G, Filioussi K, Peponi E, Bagos P, Sitaras NM. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010;25;29-35.
103. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011;131;1460-8.
104. Szekeres T, Saiko P, Fritzer-Szekeres M, Djavan B, Jager W. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann NY Acad Sci 2011;1215:89-95.
105. Joosse A, Koomen ER, Casparie MK, Herings RM, Guchelaar HJ, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009;129:2620-7.
106. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008;100:967-71. (Pubitemid 351957509)
107. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15. (Pubitemid 47073542)
108. Kovalyshyn I, Dusza SW, Siamas K, Halpern AC, Argenziano G, Marghoob AA. The Impact of Physician Screening on Melanoma Detection. Arch Dermatol 2011 [Epub ahead of print].
109. Kittler HPH, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159-65
110. Malvehy J, Puig S. Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin Dermatol 2002;20:297-304. (Pubitemid 34628901)
111. MoleSafe. MoleSafe. 2008.
112. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 2000;43:467-76. (Pubitemid 30666738)
113. Kittler H, Binder M. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Arch Dermatol 2002;138;1379.
114. Brady MS, Oliveria SA, Christos PJ, Berwick M, Coit DG, Katz J, et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000;89;342-7.
115. Fisher NM, Schaffer JV, Berwick M, Bolognia JL. Breslow depth of cutaneous melanoma: impact of factors related to surveillance of the skin, including prior skin biopsies and family history of melanoma. J Am Acad Dermatol 2005;53;393-406. (Pubitemid 41195959)
116. Carli P, De Giorgi V, Palli D, Maurichi A, Mulas P, Orlandi C et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139;607-12. (Pubitemid 36576376)
117. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996;88:17-23. (Pubitemid 26006866)
118. Goulart JM, Malvehy J, Puig S, Martin G, Marghoob AA. Dermoscopy in skin self-examination: A useful tool for select patients. Arch Dermatol 2011;147:53-8.
119. Nardone B, Martini M, Busam K, Marghoob A, West DP, Gerami P. Integrating clinical/dermatoscopic findings and fluorescence in situ hybridization in diagnosing melanocytic neoplasms with less than definitive histopathologic features. J Am Acad Dermatol 2011 [Epub ahead of print].